Betulinic acid and betulin ameliorate acute ethanol-induced fatty liver via TLR4 and STAT3 in vivo and in vitro

International Immunopharmacology

Volumn 17, Issue 2, 2013, Pages 184-190

  Wan, Ying ^a,b   Jiang, Shuang ^a   Lian, Li Hua ^a   Bai, Ting ^a   Cui, Peng He ^a   Sun, Xiao Ting ^a   Jin, Xue Jun ^a   Wu, Yan Ling ^a   Nan, Ji Xing ^a  

^a YANBIAN UNIVERSITY   (China)

^b China Medical University Siping Hospital   (China)

Author keywords

Betulin; Betulinic acid; EthanolTLR4; STAT3

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; BETULIC ACID; BETULIN; COLLAGEN TYPE 1; CYTOCHROME P450 2E1; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; FATTY LIVER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STELLATE CELL;

ALANINE AMINOTRANSFERASE; ALT; ASPARTATE AMINOTRANSFERASE; AST; BA; BETULIN; BETULINIC ACID; BT; CYP2E1; CYTOCHROME P4502E1; ETHANOL; HEPATIC STELLATE CELLS; HSCS; LIPOPOLYSACCHARIDE; LPS; SERUM TRIGLYCERIDE; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3; SREBP-1C; STAT3; STEROL REGULATORY ELEMENT-BINDING PROTEIN-1C; TG; TLR4; TOLL-LIKE RECEPTOR4; Α-SMA; Α-SMOOTH MUSCLE ACTIN;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CELL LINE; CYTOCHROME P-450 CYP2E1; FATTY LIVER, ALCOHOLIC; HEPATIC STELLATE CELLS; HUMANS; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TOLL-LIKE RECEPTOR 4; TRIGLYCERIDES; TRITERPENES;

EID: 84881494288     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.06.012     Document Type: Article

References (39)

1. Neuman MG. Cytokine-central factors in alcoholic liver disease. Alcohol Res Health 2003;27:307-16. (Pubitemid 40685570)
2. Ishak KG, Zimmerman HJ, Ray MB. Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. Alcohol Clin Exp Res 1991;15:45-66.
3. He L, Simmen FA, Ronis MJ, Badger TM. Post-transcriptional regulation of sterol regulatory element-binding protein-1 by ethanol induces class I alcohol dehydrogenase in rat liver. J Biol Chem 2004;279:28113-21. (Pubitemid 38900084)
4. Yin HQ, Kim M, Kim JH, Kong G, Kang KS, Kim HL, et al. Differential gene expression and lipid metabolism in fatty liver induced by acute ethanol treatment in mice. Toxicol Appl Pharmacol 2007;223:225-33. (Pubitemid 47371140)
5. You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 2002;277:29342-7.
6. Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 2001;7:408-13. (Pubitemid 32823990)
7. Zhao XJ, Dong Q, Bindas J, Piganelli JD,Magill A, Reiser J, et al. TRIF and IRF-3 binding to the TNF promoter results inmacrophage TNF dysregulation and steatosis induced by chronic ethanol. J Immunol 2008;181:3049-56.
8. Petrasek J, Dolganiuc A, Csak T, Nath B, Hritz I, Kodys K, et al. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology 2011;53:649-60.
9. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-52. (Pubitemid 29468238)
10. Szabo G, Dolganiuc A, Dai Q, Pruett SB. TLR4, ethanol, and lipid rafts: a new mechanism of ethanol action with implications for other receptor-mediated effects. J Immunol 2007;178:1243-9. (Pubitemid 46154592)
11. Hritz I, Mandrekar P, Velayudham A, Catalano D, Dolganiuc A, Kodys K, et al. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008;48:1224-31.
12. Nanji AA, Khettry U, Sadrzadeh SMH, Yamanaka T. Severity of liver injury in experimental alcoholic liver disease: correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol 1993;142:367-73. (Pubitemid 23057448)
13. Enomoto N, Ikejima K, Bradford B, Rivera C, Kono H, Brenner DA, et al. Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. Gastroenterology 1998;115:443-51.
14. Larrea E, Aldabe R, Molano E, Fernandez-Rodriguez CM, Ametzazurra A, Civeira MP, et al. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies. Gut 2006;55:1188-96. (Pubitemid 44085689)
15. Horiguchi N, Ishac EJ, Gao B. Liver regeneration is suppressed in alcoholic cirrhosis: correlation with decreased STAT3 activation. Alcohol 2007;41:271-80. (Pubitemid 47042332)
16. Stärkel P, De Saeger C, Leclercq I, Strain A, Horsmans Y. Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. J Hepatol 2005;43:687-95. (Pubitemid 41253237)
17. Sami A, Taru M, Salme K, Jari Y. Pharmacological properties of the ubiquitous natural product betulin. Pharm Acta Helv 2006;29:1-13.
18. Wan Y, Wu YL, Lian LH, Xie WX, Li X, OuYang BQ, et al. The anti-fibrotic effect of betulinic acid is mediated through the inhibition of NF-?B nuclear protein translocation. Chem Biol Interact 2012;195:215-23.
19. Szuster-Ciesielska A, Kandefer-SzerszenM. Protective effects of betulin and betulinic acid against ethanol-induced cytotoxicity in HepG2 cells. Pharmacol Rep 2005;57: 588-95.
20. Zeng T, Zhang CL, Song FY, Zhao XL, Yu LH, Zhu ZP, et al. Betulin and betulinic acid attenuate ethanol-induced liver stellate cell activation by inhibiting reactive oxygen species (ROS), cytokine (TNF-α, TGF-β) production and by influencing intracellular signaling. Toxicology 2012;296:56-66.
21. Szuster-Ciesielska A, Sztanke K, Kandefer-Szerszen M. A novel fused 1,2,4-triazine aryl derivative as antioxidant and nonselective antagonist of adenosine A2A receptors in ethanol-activated liver stellate cells. Chem Biol Interact 2012;195:18-24.
22. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31. (Pubitemid 34496588)
23. Wang H, Lafdil F, Kong XN, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci 2011;7:536-50.
24. You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol 2004;34:39-43.
25. Zhao Z, Yu M, Crabb D, Xu Y, Liangpunsakul S. Ethanol-induced alterations in fatty acid-related lipids in serum and tissues in mice. Alcohol Clin Exp Res 2011;35: 229-34.
26. Thurman RG, Bradford BU, Iimuro Y, Knecht KT, Arteel GE, Yin M, et al. The role of gut-derived bacterial toxins and free radicals in alcohol-induced liver injury. J Gastroenterol Hepatol 1998;13:S39-50. (Pubitemid 28446561)
27. Wu D, Wang X, Zhou R, Yang L, Cederbaum AI. Alcohol steatosis and cytotoxicity: the role of cytochrome P4502E1 and autophagy. Free Radic Biol Med 2012;53: 1346-57.
28. Lian LH, Wu YL, Song SZ, Wan Y, Xie WX, Li X, et al. Gentiana manshurica Kitagawa reverses acute alcohol-induced liver steatosis through blocking sterol regulatory element-binding protein-1 maturation. J Agric Food Chem 2010;58: 13013-9.
29. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011;53: 96-105.
30. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009;50:638-44.
31. Schmid D, Gruber M, Piskaty C, Woehs F, Renner A, Nagy Z, et al. Inhibition of NF-κB-dependent cytokine and inducible nitric oxide synthesis by the macrocyclic ellagitannin oenothein B in TLR-stimulated RAW 264.7 macrophages. J Nat Prod 2012;75:870-5.
32. McDermott EMP, O'Neill LAJ. Signal transduction by the lipopolysaccharide receptor Toll-like receptor-4. Immunology 2004;113:153-62. (Pubitemid 39312442)
33. Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006;574:41-53. (Pubitemid 43905795)
34. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 2010;52:1291-300.
35. Yang L, Zhang YX, Wang LD, Fan FJ, Zhu L, Li ZQ, et al. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J Hepatol 2010;53:339-47.
36. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2005;2(2):92-100.
37. Horiguchi N, Lafdil F, Miller AM, Park O, Wang H, Rajesh M, et al. Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice. Hepatology 2010;51(5):1724-34.
38. Horiguchi N, Wang L, Mukhopadhyay P, Park O, Jeong WI, Lafdil F, et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008;134:1148-58. (Pubitemid 351451970)
39. Miller AM, Wang H, Park O, Horiguchi N, Lafdil F, Mukhopadhyay P, et al. Antiinflammatory and anti-apoptotic roles of endothelial cell STAT3 in alcoholic liver injury. Alcohol Clin Exp Res 2010;34(4):719-25.